IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
- Conditions
- Urinary IncontinenceOveractive Bladder
- Interventions
- Biological: Botulinum toxin type ADrug: Placebo
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 227
- Registration Number
- NCT02660138
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Urology Clinics of North Texas, Dallas, Texas, United States
🇺🇸Delaware Valley Urology,IIC, Voorhees, New Jersey, United States
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
- Conditions
- Urinary IncontinenceOveractive Bladder
- Interventions
- Biological: Botulinum toxin type ADrug: Placebo
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 258
- Registration Number
- NCT02660359
- Locations
- 🇨🇴
Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia
🇨🇱Clínica Uromed, Santiago, Chile
🇨🇴Solano & Terront Servicios Medicos LTDA- Unidad Integral de Endocrinologia, Bogotá, Colombia
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
- Conditions
- Pancreatic TumoursMidgut Neuroendocrine Tumours
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 99
- Registration Number
- NCT02651987
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇪🇸Hospital Universitario Vall D'hebron, Barcelona, Spain
🇧🇪Erasme Hospital, Bruxelles, Belgium
Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.
- Conditions
- Prostate Cancer
- Interventions
- Drug: Gonadotropin-releasing Hormone (GnRH) agonist therapy
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 1000
- Registration Number
- NCT02630641
- Locations
- 🇫🇷
Ipsen Central Contact, Paris, France
Eziclen Drug Utilisation in Real Life Setting
- Conditions
- Bowel Cleansing
- Interventions
- Drug: Eziclen®/Izinova®
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 1286
- Registration Number
- NCT02630680
- Locations
- 🇨🇿
Ustredni vojenska nemocnice, Praha, Czechia
🇩🇪Gemeinschaftspraxis Dres. Klausmann, Aschaffenburg, Germany
🇨🇿Krajská zdravotní, a.s., nemocnice Teplice, Teplice, Czechia
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Interventions
- Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 404
- Registration Number
- NCT02630654
- Locations
- 🇱🇻
Riga East University Hospital, Riga, Latvia
🇪🇪North Estonia Medical Center, Tallinn, Estonia
🇱🇻Pauls Stradins Clinical University Hospital, Riga, Latvia
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
- Conditions
- Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT02592707
- Locations
- 🇺🇸
MD Anderson Cancer Center, Department of Nuclear Medicine, Houston, Texas, United States
🇦🇺Peter MacCallum Cancer Centre, Molecular Imaging and Targeted Therapeutics Laboratory, East Melbourne, Australia
🇦🇺Ramsay Hollywood Private Hospital, Department of Nuclear Medicine, Perth, Australia
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 56
- Registration Number
- NCT02551991
- Locations
- 🇪🇸
Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain
🇪🇸Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues
- Conditions
- Prostate Cancer
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 470
- Registration Number
- NCT02542501
- Locations
- 🇵🇹
Hospital Universitário de Coimbra, Coimbra, Portugal
🇵🇹Hospital de São José, Lisboa, Portugal
🇵🇹Hospital de Santa Maria, Lisboa, Portugal
Validation Study of the SAGIT® Instrument in Acromegaly
- Conditions
- Acromegaly
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 227
- Registration Number
- NCT02539927
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸The Emory Pituitary Center, Atlanta, Georgia, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States